Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2025-10-30 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于核心技术人员离职的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the resignation of a core technical personnel from the company. It details the individual's background, the impact of their departure on the company, and the company's measures to maintain its technical capabilities. There is no financial data, no mention of financial results, no regulatory filings, no voting results, no capital changes, or any other report type. This is a management-related announcement about personnel changes, specifically about a senior technical staff member leaving the company. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes in senior management or key personnel.
2025-10-30 Chinese
圣湘生物科技股份有限公司关于与专业机构共同投资设立基金暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's investment in a fund jointly established with professional institutions, which constitutes a related party transaction. It details the investment amount, partners involved, and the nature of the transaction. It explicitly states that this transaction is a related party transaction and not a major asset restructuring, and it does not require shareholder meeting approval. The document is a formal announcement of a capital investment and related party transaction, not a financial report, earnings release, or management discussion. It fits the category of Capital/Financing Update (CAP) because it updates on the company's financing activities and capital commitments related to the fund investment.
2025-10-21 Chinese
圣湘生物科技股份有限公司关于自愿披露相关产品取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 圣湘生物科技股份有限公司 regarding the voluntary disclosure of obtaining a medical device registration certificate for certain nucleic acid test kits. It details the product registration information, the impact on the company, and risk warnings. The document is short (1477 characters) and focuses on regulatory approval and product information rather than financial data or detailed reports. There is no indication of financial statements, management discussion, or earnings data. It is not a report but an announcement about a regulatory approval event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-09-30 Chinese
圣湘生物科技股份有限公司关于自愿披露相关产品取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 圣湘生物科技股份有限公司 regarding the voluntary disclosure of obtaining a medical device registration certificate for a specific product. It details the product registration information, its intended use, and the potential impact on the company. The document is relatively short (1483 characters) and does not contain financial statements, detailed financial performance, or comprehensive report data. It is an official announcement about a regulatory approval related to the company's product, not a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-09-19 Chinese
湖南启元律师事务所关于圣湘生物科技股份有限公司差异化权益分派事项之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding a company's differentiated equity distribution related to its 2025 semi-annual profit distribution. It references relevant laws and regulations, the company's board resolutions, and details the calculation and impact of the equity distribution on stock prices. The document is a legal opinion on a specific corporate action rather than a financial report, earnings release, or regulatory announcement. It does not contain financial statements or earnings data but provides a legal assessment of the equity distribution scheme. Given the nature of the document as a legal opinion letter related to a corporate action, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-09-16 Chinese
圣湘生物科技股份有限公司2025年半年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an "Implementation Announcement of the 2025 Semi-Annual Equity Distribution" by 圣湘生物科技股份有限公司. It details the dividend distribution plan for the 2025 half-year period, including dividend per share, relevant dates (record date, ex-dividend date, payment date), authorization by the shareholders' meeting, and tax treatment for different shareholders. The document is an announcement of the dividend amount and payment details rather than a full financial report or earnings release. It is also relatively short (3520 characters) and focuses on dividend distribution specifics. Therefore, it fits the category of "Notice of Dividend Amount" (DIV).
2025-09-16 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.